Vaccine efficacy in adults in a respiratory syncytial virus challenge study
B Schmoele-Thoma, AM Zareba, Q Jiang… - … England Journal of …, 2022 - Mass Medical Soc
Background Although human respiratory syncytial virus (RSV) is an important cause of
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …
Vaccine efficacy in adults in a respiratory syncytial virus challenge study.
B Schmoele-Thoma, AM Zareba, Q Jiang, MS Maddur… - 2022 - cabidigitallibrary.org
Background: Although human respiratory syncytial virus (RSV) is an important cause of
illness and death in older adults, no RSV vaccine has been licensed. Methods: In a phase …
illness and death in older adults, no RSV vaccine has been licensed. Methods: In a phase …
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
B Schmoele-Thoma, AM Zareba, Q Jiang… - The New England …, 2022 - europepmc.org
Background Although human respiratory syncytial virus (RSV) is an important cause of
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
B Schmoele-Thoma, AM Zareba, Q Jiang, MS Maddur… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Although human respiratory syncytial virus (RSV) is an important cause of
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …
illness and death in older adults, no RSV vaccine has been licensed. Methods In a phase 2a …